Insider trade

Tempest Therapeutics (TPST): Director received 25K units

Nancy Freda Smith, Director at Tempest Therapeutics, reported a grant / award of 25K units.

25K
Derivative units
Traded
Sep 22, 2026
Filed
Oct 2, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Aug 13, 2026Company filing · Form 8-K · ResultsReported its results
  2. Aug 13, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them
  3. Aug 18, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On August 18, 2026, Mr. Justin Trojanowski notified Tempest Therapeutics, Inc. (the “Company”) of his decision to resign from his positions as Principal Financial Officer and Principal Accounting Officer of the Company, and from any and all other positions he holds with the Company, effective as of September 1, 2026.”
  4. Sep 11, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them
  5. Sep 14, 2026Company filing · Form 8-K · Material agreement, Reg FDSigned an important agreement, and shared information with investors
  6. Sep 22, 2026Company filing · Form 8-K · Material agreement, Executive changeChanged a top executive or board member, and signed an important agreement (and 1 more item)“Effective September 22, 2026, the Board appointed Ms. Nancy Freda-Smith as Class III director to fill a vacancy on the Board. Ms. Freda-Smith will serve until the Company’s 2027 annual meeting of stockholders and until her successor is duly elected and qualified, or until her earlier death, resignation or removal.”

What came next

  1. Oct 13, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“Effective October 13, 2026, the Board of Directors (the “Board”) of Tempest Therapeutics, Inc. (the “Company”) appointed Mr. John Frederick as a Class III director of the Board.”
  2. Oct 26, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On October 26, 2026, Ms. Constance Ames confirmed to Tempest Therapeutics, Inc. (the “Company”) that she would be resigning from her position as Chief Financial Officer of the Company and from any and all other positions she holds with the Company for personal considerations unrelated to the Company, effective immediately.”
  3. Nov 4, 2026Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“On November 4, 2026, Tempest Therapeutics, Inc., a Delaware corporation (the “Company”), received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days, the bid price of the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing…”
  4. Nov 13, 2026Company filing · Form 8-K · ResultsReported its results
  5. Nov 20, 2026Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“As previously reported, on May 19, 2026, Tempest Therapeutics, Inc., a Delaware corporation (the “Company”), received a notice from the Listing Qualifications Staff (“Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(1) (the “Minimum Stockholders’ Equity Rule”) because the Company reported stockholders’ equity of less than $2.5 million…”
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Tempest Therapeutics

OQRO holds no insider, Congress, fund or contract record for Tempest Therapeutics dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its TPST page.

How this filing works

Explore the data

Common questions

Which Tempest Therapeutics (TPST) insider traded, and how much?

Nancy Freda Smith, Director at Tempest Therapeutics, reported a grant / award of 25K units. Not an open-market trade.

When did it happen, and when was it made public?

Traded: Sep 22, 2026. Filed: Oct 2, 2026. That is 10 days between the two dates.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

Does this mean TPST stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Tempest Therapeutics

Everything OQRO holds on this company is on its TPST page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data